Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies ...

The global Custom Antibody Market is valued at USD 553.05 Million in 2024 and is projected to reach a value of USD 1237.1 ...

Monoclonal antibodies (mAbs) offer promise as effective tumor targeting and drug delivery agents for cancer therapy. However, comparative biological and clinical characteristics of mAbs targeting the ...

In a bold move that could reshape the future of biomedical research, Boster Bio is launching a Free Antibody Validation ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

These properties make SA invaluable in biomolecule capture and enrichment in analytical applications such as ELISA, protein ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has ...

Should a woman present with anti-D antibodies, the clinician will be prospectively prepared with a review of blood antigens, antibody production, and current fetal surveillance techniques.

Significant correlations were observed between antibody affinities and some atypical memory B cells.In conclusion, our study shows that development of naturally acquired slowly dissociating (high ...